- Home
- PRAX vs RGR Comparison
PRAX vs RGR Comparison
Compare PRAX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- RGR
- Stock Information
- Founded
- PRAX 2015
- RGR 1949
- Country
- PRAX United States
- RGR United States
- Employees
- PRAX N/A
- RGR N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- PRAX Health Care
- RGR Industrials
- Exchange
- PRAX Nasdaq
- RGR Nasdaq
- Market Cap
- PRAX 599.7M
- RGR 627.3M
- IPO Year
- PRAX 2020
- RGR N/A
- Fundamental
- Price
- PRAX $33.79
- RGR $39.29
- Analyst Decision
- PRAX Strong Buy
- RGR
- Analyst Count
- PRAX 9
- RGR 0
- Target Price
- PRAX $123.33
- RGR N/A
- AVG Volume (30 Days)
- PRAX 570.3K
- RGR 141.4K
- Earning Date
- PRAX 05-12-2025
- RGR 04-30-2025
- Dividend Yield
- PRAX N/A
- RGR 1.78%
- EPS Growth
- PRAX N/A
- RGR N/A
- EPS
- PRAX N/A
- RGR 1.77
- Revenue
- PRAX $8,553,000.00
- RGR $535,643,000.00
- Revenue This Year
- PRAX N/A
- RGR $4.74
- Revenue Next Year
- PRAX $789.73
- RGR N/A
- P/E Ratio
- PRAX N/A
- RGR $22.20
- Revenue Growth
- PRAX 249.53
- RGR N/A
- 52 Week Low
- PRAX $26.70
- RGR $34.11
- 52 Week High
- PRAX $91.83
- RGR $47.28
- Technical
- Relative Strength Index (RSI)
- PRAX 43.73
- RGR 54.97
- Support Level
- PRAX $28.79
- RGR $37.29
- Resistance Level
- PRAX $30.88
- RGR $39.45
- Average True Range (ATR)
- PRAX 3.07
- RGR 0.92
- MACD
- PRAX 0.88
- RGR 0.01
- Stochastic Oscillator
- PRAX 56.05
- RGR 87.60
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.